Le syndrome myasthénique de Lambert-Eaton (LEMS): un trouble présynaptique auto-immun rare souvent associé au cancer

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Avatar du membre

Auteur du sujet
Messages : 5163
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 10 Firefox
Genre :
Zodiaque :
Âge : 61
Contact :

Le syndrome myasthénique de Lambert-Eaton (LEMS): un trouble présynaptique auto-immun rare souvent associé au cancer

Message par Pboulanger » 19 juin 2017 10:07


Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28608304

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B1, Eymard B2, Datt J3, Mantegazza R4.
J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541-9.


Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular junction disorder that is related to the loss of functional P/Q-type voltage-gated calcium channels (VGCCs) on presynaptic nerve terminals.

Up to 60% of cases occur as a paraneoplastic disorder (SCLC-LEMS), most commonly in association with small cell lung cancer.

The remaining cases have an idiopathic non-tumor etiology but are associated with underlying autoimmune disease (NT-LEMS).

Patients with LEMS invariably experience progressive proximal muscle weakness, often accompanied by general fatigue and autonomic symptoms. Some LEMS clinical symptoms overlap with those of other myasthenic syndromes, most commonly myasthenia gravis, which can contribute to misdiagnosis or delayed diagnosis.

Prognosis is related to the presence of cancer or autoimmune disease and the severity/distribution of muscle weakness.

Cause of death in patients with SCLC-LEMS is typically tumor progression, whereas NT-LEMS does not reduce life expectancy.

LEMS diagnosis is supported by a threefold approach: clinical features, electromyography, and anti-VGCC antibody serology. LEMS is a clinically important early indicator of possible cancer; therefore, a LEMS diagnosis should immediately prompt rigorous oncological screening and surveillance. Symptomatic treatment of LEMS typically involves medications that improve neurotransmission (e.g., the potassium channel blocker amifampridine [3,4-diaminopyridine]), with addition of immunosuppressants/modulators (e.g., prednisone plus azathioprine) in individuals with persistent symptoms.

Where a tumor is identified, oncological treatment should take priority.

It should be remembered, however, that LEMS has a significant impact on a patient's quality of life and ability to perform daily activities, and therefore warrants timely diagnosis and appropriate treatment in and of itself.



Retourner vers « Informations »